Entera Bio Ltd., a clinical stage company, focuses on developing oral peptide or protein replacement therapies for unmet medical needs where an oral tablet form holds the potential to transform the standard of care. The company leverage its N-Tab, an oral delivery technology, which is designed to simultaneously stabilize the peptide in the gastrointestinal tract and promote its absorption into the bloodstream. Its advanced product candidate is EB613 (oral PTH (1-34)) that is entering into Phase 3 development as the first oral, osteoanabolic (bone-building) once-daily tablet treatment for post-menopausal women with low bone mineral density and high-risk osteoporosis. The company is also developing EB612 as the first oral PTH(1-34) tablet peptide replacement therapy for hypoparathyroidism. In addition, it is developing the first oral oxyntomodulin, a dual targeted GLP1/glucagon peptide, in tablet form for the treatment of obesity; and the first oral GLP-2 peptide tablet as an injection-free alternative for patients suffering from rare malabsorption conditions, such as short bowel syndrome. The company has research collaboration agreement with OPKO Biologics, Inc. Entera Bio Ltd. was incorporated in 2009 and is based in Jerusalem, Israel.

Period	Debt/Equity
2018-12-31	-1.11
2019-12-31	0.35
2020-12-31	0.29
2021-12-31	0.15
2022-12-31	0.12
2023-12-31	0.13
2024-12-31	0.16

	A	B	C	D
1	Symbol	Price	Change	Volume
2	ENTX	$1.16	-1.28%	0.04M
3
4
5

Entera Bio Ltd. (ENTX) Debt to Equity Ratio

Debt to Equity Ratio Data

Get Entera Bio Ltd. Data in Excel

More ENTX Financial Data